An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.

The role of latent membrane protein 2 (LMP2) in Epstein-Barr virus (EBV) infection was evaluated by using latently infected primary B lymphocytes that had been growth transformed by wild-type or specifically mutated EBV recombinants. LMP2 null mutant recombinant EBV-infected cells were similar to normal B lymphocytes in their rapid increase in intracellular free calcium after surface immunoglobulin crosslinking. These cells also became more permissive for lytic EBV replication. In sharp contrast, wild-type control infected cells had little or no increase in intracellular free calcium or in permissivity for EBV replication. The block to surface immunoglobulin crosslinking-induced permissivity in cells expressing wild-type LMP2 could be bypassed by raising intracellular free calcium levels with an ionophore and by activating protein kinase C with phorbol 12-myristate 13-acetate. LMP2A, not LMP2B, mediates this effect on calcium mobilization. Genetic and biochemical data are consistent with these effects being due to the interaction of the LMP2A N-terminal cytoplasmic domain with B lymphocyte src family tyrosine kinases.

[1]  A. Mindel.  The Human Herpes Viruses , 1994 .

[2]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Kieff,et al.  Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B , 1993, Journal of virology.

[4]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes , 1993, Journal of virology.

[5]  E. Kieff,et al.  The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro , 1993, Journal of virology.

[6]  J. Cambier,et al.  Membrane immunoglobulin and its accomplices: new lessons from an old receptor 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  E. Kieff,et al.  An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases , 1992, Journal of virology.

[8]  D. Rowe,et al.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes , 1992, Journal of virology.

[9]  I. Mellinghoff,et al.  Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. , 1991, Virology.

[10]  E. Kieff,et al.  An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase , 1991, Journal of virology.

[11]  I. Mellinghoff,et al.  Effect of genistein, a tyrosine kinase inhibitor, on latent EBV activation induced by cross-linkage of membrane IgG in Akata B cells. , 1991, Journal of immunology.

[12]  G. Packham,et al.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia , 1991, Journal of virology.

[13]  K. Takada,et al.  Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. , 1990, Journal of immunology.

[14]  I. Joab,et al.  Identification of the Epstein-Barr virus terminal protein gene products in latently infected lymphocytes , 1990, Journal of virology.

[15]  G. Lenoir,et al.  Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera , 1990, Journal of virology.

[16]  E. Kieff,et al.  A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1 , 1990, Journal of virology.

[17]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 , 1990, Journal of virology.

[18]  M. Yacoub,et al.  Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. , 1990, Transplantation.

[19]  P. Farrell,et al.  The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. , 1989, The Journal of general virology.

[20]  E. Kieff,et al.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. , 1989, The New England journal of medicine.

[21]  M. Reth.  Antigen receptor tail clue , 1989, Nature.

[22]  E. Kieff,et al.  Two related Epstein-Barr virus membrane proteins are encoded by separate genes , 1989, Journal of virology.

[23]  K. Takada,et al.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes , 1989, Journal of virology.

[24]  E. Kieff,et al.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity , 1988, Journal of virology.

[25]  E. Kieff,et al.  The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts , 1988, Journal of virology.

[26]  V. Baichwal,et al.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.

[27]  M. Perricaudet,et al.  A spliced Epstein‐Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. , 1988, The EMBO journal.

[28]  S. Grimaldi,et al.  TPA induction of Epstein‐Barr virus early antigens in Raji cells is blocked by selective protein kinase‐C inhibitors , 1987, International journal of cancer.

[29]  S. Grimaldi,et al.  Calcium modulation activates Epstein-Barr virus genome in latently infected cells. , 1986, Science.

[30]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[31]  J. Sklar,et al.  LYMPHOPROLIFERATIVE DISORDERS IN CARDIAC TRANSPLANT RECIPIENTS ARE MULTICLONAL LYMPHOMAS , 1984, The Lancet.

[32]  J. Poduslo,et al.  Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen. , 1984, Virology.

[33]  K. Takada.  Cross‐linking of cell surface immunoglobulins induces epstein‐barr virus in burkitt lymphoma lines , 1984, International journal of cancer.

[34]  L. Heston,et al.  New Epstein–Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma , 1982, Nature.

[35]  E. Unanue,et al.  Crosslinking by ligands to surface immunoglobulin triggers mobilization of intracellular 45Ca2+ in B lymphocytes , 1979, The Journal of cell biology.

[36]  G. Miller,et al.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Miller,et al.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.